- Montérégie Integrated Cancer Center, part of Charles-LeMoyne
Hospital, is a center of excellence and recognized leader in the
treatment of cancer in the province of Quebec
- The Radixact System is equipped with ClearRT™ and
Synchrony®, advanced technologies designed to improve
treatment outcomes for more patients each day
MADISON,
Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the team at
Quebec's Montérégie Integrated
Cancer Center, part of Charles-LeMoyne Hospital, is the first in
Canada to treat cancer patients
using the company's Radixact® radiation therapy delivery
system. According to the Quebec Cancer Foundation, "on average in
Quebec, someone learns that they
have cancer every 8 minutes1," reinforcing the need for
innovative new care options like the Radixact System that
effectively manage the disease while minimizing the radiation dose
to healthy tissue and associated risk of side effects that can
impact daily life. A second Radixact System is scheduled to be
installed mid-2024.
The Radixact System at the Montérégie center has been augmented
with the Accuray exclusive ClearRT™ helical fan-beam kVCT imaging
solution and Synchrony® motion adaptation
technology. ClearRT can produce exceptional, diagnostic-like
quality CT images while Synchrony enables clinicians to track,
detect and correct for tumor movement in real-time, providing
medical care teams with the tools to help improve radiation therapy
department workflows and patient outcomes, and rapidly deliver
treatments.
"Our goal at Accuray is to design radiation therapy solutions
that can take on the most complex challenges — while making
commonly treatable cases even easier — so patients get back to
living their lives, faster. We are honored to partner with the
Montérégie Integrated Cancer Center team to bring a new approach
for the treatment of cancer to the people in the province of
Quebec. With the installation of
the Radixact System, ClearRT and Synchrony, the Montérégie team is
setting a new standard for precision and accuracy in radiation
therapy and making this form of care an option for more cancer
patients," said Suzanne Winter,
president and CEO of Accuray.
The Radixact System provides a non-invasive option for the
treatment of a wide range of cancerous and non-cancerous tumors
throughout the body — from small to large tumors, multiple tumors,
those located in hard-to-reach areas and recurrent tumors, to
cancers of the skin and blood. The system can be used in
combination with surgery, chemotherapy and other medications. It
also can be used as part of the pre-conditioning regimen before a
bone marrow transplant, either alone or with chemotherapy, to
neutralize any cancer in the marrow.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, X,
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations regarding the
treatment of cancer in Quebec,
Canada; expectations regarding installation of a second
Radixact at the Monteregi Integrated Cancer Center; clinical
applications; clinical results; patient experiences and patient
outcomes. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products,
including new product innovations and releases; the company's
ability to develop new products or improve existing products to
meet customers' needs; the company's ability to anticipate or keep
pace with changes in the marketplace; and the direction of
technological innovation and customer demands and such other risks
identified under the heading "Risk Factors" in the company's
Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on February
7, 2024, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
¹
https://cancerquebec.ca/en/information-about-cancer/the-cancer/statistics/#:~:text=In%202023%2C%2067%2C548%20Quebecers%20were,of%20aging%20and%20population%20growth.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/quebec-cancer-center-is-first-in-canada-to-treat-cancer-patients-using-the-accuray-radixact-system-302060306.html
SOURCE Accuray Incorporated